@article{article, title  = {{Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1}},

 publisher = {{Springer Science and Business Media LLC}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/207863 http://dx.doi.org/10.1007/s40257-023-00817-0 }},

 year = {{2023}},

 month = {{10}},

 author = {{Simpson EL and Blauvelt A and Silverberg JI and Cork MJ and Katoh N and Mark T and Schneider SKR and Wollenberg A}},

 doi = {{10.1007/s40257-023-00817-0}},

 volume = {{25}},

 journal = {{American Journal of Clinical Dermatology}},

 pages = {{139-148}},

 note = {{Accessed on 2025/11/05}}}